«Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper
support and
efforts we could translate our findings into
experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers,» said Pellecchia, who serves as the founding director of the Center for Molecular and Translational Medicine at UCR.
Subsequent investigations did not
support the claim, but the excitement got physicists thinking — and more often than not, new thinking leads to new
experimental efforts.